List of Excipients in Branded Drug METOPROLOL SUCCINATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	HYPROMELLOSE
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	PARAFFIN
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	POLYETHYLENE GLYCOL

Generic Drugs Containing METOPROLOL SUCCINATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	ETHYLCELLULOSE
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	HYPROMELLOSE

What are the Most Frequently-Used Excipients in METOPROLOL SUCCINATE?

# Of NDCs	Excipient
124	ACETYLTRIBUTYL CITRATE
8	ALCOHOL
3	CALCIUM STEARATE

Metoprolol Succinate Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Metoprolol succinate extended-release tablets are a mature, high-volume generic opportunity. The commercial advantage is unlikely to come from the active pharmaceutical ingredient, which is widely available and off-patent. Value is concentrated in release-control architecture, bioequivalence execution, dose flexibility, excipient cost, supply reliability, and differentiated delivery formats.

The most attractive development paths are low-cost extended-release generics, line extensions that improve administration for swallowing-impaired patients, and contract-manufactured products for regional markets. The principal technical risk is reproducing the reference product’s in-vitro and in-vivo release profile across the full 25 mg, 50 mg, 100 mg, and 200 mg strength range.

What is metoprolol succinate and how is it marketed?

Metoprolol succinate is the extended-release salt form of metoprolol, a selective beta-1 adrenergic receptor blocker. The reference product, Toprol-XL, is approved for hypertension, angina pectoris, and stable, symptomatic heart failure of ischemic, hypertensive, or cardiomyopathic origin. FDA labeling directs once-daily administration and prohibits crushing or chewing the tablets because these actions can disrupt extended release (FDA, 2023a).

Attribute	Commercial profile
Active ingredient	Metoprolol succinate
Dosage form	Extended-release tablet
Reference product	Toprol-XL
Original sponsor	AstraZeneca
FDA application	NDA 019962
Strengths	25 mg, 50 mg, 100 mg, 200 mg
Primary indications	Hypertension, angina, stable symptomatic heart failure
Administration	Once daily
Generic pathway	ANDA with comparative bioequivalence
Main technical issue	Reproducing controlled release and dose proportionality
Main commercial issue	Price competition and channel access

Metoprolol tartrate is an immediate-release or conventional-release product administered more frequently. It is not an interchangeable substitute for metoprolol succinate extended-release tablets without the appropriate regulatory basis.

What excipients are used in metoprolol succinate extended-release tablets?

The excipient system typically combines a hydrophilic matrix or pellet core with a polymeric release-control layer. Exact compositions vary by manufacturer and may differ across strengths.

Common excipient classes include:

Excipient class	Examples	Function
Diluent or filler	Lactose monohydrate, microcrystalline cellulose	Tablet mass, compressibility
Matrix former	Hypromellose	Swelling and diffusion control
Film former or barrier polymer	Ethylcellulose	Slows water penetration and drug diffusion
Superdisintegrant	Sodium starch glycolate	Promotes tablet breakup where appropriate
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, stearic acid	Reduces die-wall friction
Coating aid	Polyethylene glycol, hypromellose	Film flexibility and coating performance
Opacifier or colorant	Titanium dioxide, iron oxides	Appearance and light protection
Processing solvent	Water or hydroalcoholic systems	Polymer and film application

The Toprol-XL label identifies a controlled-release tablet containing metoprolol succinate and inactive ingredients including hypromellose, ethylcellulose, lactose, sodium starch glycolate, silicon dioxide, magnesium stearate, polyethylene glycol, and titanium dioxide, although excipients can differ by strength and manufacturing site (FDA, 2023a).

Why the excipient system matters

Metoprolol succinate is highly soluble, creating a release-control challenge. A formulation that relies only on rapid disintegration can produce an unacceptable release rate. Developers generally need a matrix, coated-pellet, or multiparticulate approach to limit the initial burst and maintain exposure over approximately 24 hours.

The critical formulation variables include:

• Polymer viscosity grade.
• Polymer concentration.
• Granule or pellet size.
• Coating weight gain.
• Tablet compression force.
• Porosity and hardness.
• Lubrication level.
• Drug loading.
• Dissolution medium and agitation conditions.
• Water activity and residual solvent.

Small changes in polymer hydration or coating permeability can shift the early release profile. These effects are important because beta blockers can produce clinically relevant changes in heart rate and blood pressure when exposure rises too rapidly.

What excipient strategies are most commercially attractive?

Hydrophilic matrix tablets

Hypromellose-based matrices are the lowest-cost platform for a conventional generic product. They support standard wet granulation, dry granulation, or direct compression, depending on drug loading and powder flow.

Advantages include:

• Low raw-material cost.
• Broad supplier availability.
• Straightforward scale-up.
• Compatibility with standard tablet presses.
• Simple manufacturing-site transfer.

Risks include sensitivity to compression force, polymer hydration, tablet dimensions, and dissolution-method conditions. A matrix formulation can also exhibit strength-dependent release behavior if the 25 mg and 200 mg tablets are not proportionally designed.

Ethylcellulose-based matrices or coatings

Ethylcellulose can reduce water penetration and drug diffusion. It is useful in a matrix or as a coating over drug-containing particles.

The commercial benefit is better control of the initial release phase. The disadvantages are greater process complexity, solvent or dispersion management, and tighter control of coating uniformity. Ethylcellulose grade, particle size, plasticizer concentration, and coating weight gain can materially affect the release curve.

Coated multiparticulates

A multiparticulate system places metoprolol succinate in pellets or granules that receive a polymeric membrane before compression into a tablet.

This design can improve dose uniformity and reduce sensitivity to local tablet defects. It also creates opportunities for:

• Sprinkle formulations.
• Capsules containing controlled-release pellets.
• Orally disintegrating presentations.
• Flexible dose combinations.
• Lower-dose pediatric or geriatric products.

The main barrier is manufacturing cost. Pellet formation, layering, coating, curing, and compression require more equipment and process controls than a basic matrix tablet.

Low-cost direct-compression platforms

A direct-compression product can reduce manufacturing steps and improve operating margins. The approach depends on a powder blend with sufficient flow, content uniformity, compressibility, and segregation resistance.

Co-processed excipients may improve tableting performance, but they can increase material cost and create additional supplier qualification work. A lower-cost conventional excipient system is generally preferable for a highly commoditized product unless it materially improves yield or dissolution consistency.

What formulations are protected by metoprolol succinate patents?

The principal historical intellectual-property value was associated with controlled-release formulations rather than the metoprolol succinate molecule itself. The original Toprol-XL formulation patents have expired, eliminating the principal U.S. patent barrier to conventional generic development.

IP category	Current commercial relevance
Metoprolol molecule	Off-patent
Succinate salt	Historic protection largely expired
Original controlled-release formulation	Historic patents expired
Tablet composition	May be covered by later patents in some jurisdictions, but broad U.S. barriers are limited
Manufacturing process	Potentially relevant if a process is novel and non-obvious
Sprinkle or orally disintegrating format	Possible formulation and method-of-use filings
Combination product	Separate patent and regulatory analysis required
Device-enabled delivery	Potentially protectable, but not central to current tablet demand

The practical constraint is less the expired core patent estate and more regulatory proof. A company must establish that its product is pharmaceutically equivalent and bioequivalent to the reference listed drug under the applicable FDA pathway.

What is the FDA regulatory and Orange Book status of metoprolol succinate?

Toprol-XL is an FDA-approved extended-release product under NDA 019962. Generic metoprolol succinate extended-release tablets have been approved through ANDAs and are listed in FDA product databases by multiple applicants (FDA, 2023b).

The relevant regulatory issues are:

1. Pharmaceutical equivalence to the reference product.
2. Bioequivalence under FDA’s modified-release guidance.
3. Matching approved strengths and labeling.
4. Demonstrating appropriate dissolution similarity.
5. Controlling dose dumping risk.
6. Establishing stability through the proposed shelf life.
7. Satisfying manufacturing and quality requirements under 21 C.F.R. Parts 210 and 211.

The Orange Book identifies the reference listed drug, approved strengths, dosage form, and therapeutic equivalence ratings. Because approved applicants and patent certifications can change, the current FDA Orange Book record should control any launch, acquisition, or Paragraph IV analysis (FDA, 2024).

For a conventional generic entrant, the historic formulation patent expiry means a Paragraph IV strategy is generally less central than it was during the original Toprol-XL exclusivity period. Commercial timing depends more on ANDA approval, tentative or final approval status, market concentration, supply agreements, and state substitution practices.

When did metoprolol succinate lose exclusivity?

The original Toprol-XL market exclusivity ended years before the current generic market developed. The product’s principal controlled-release patents expired in the late 2000s, and generic products subsequently entered the U.S. market.

Exclusivity category	Assessment
New chemical entity exclusivity	Expired
Original formulation patents	Expired
Pediatric exclusivity	Not a current barrier
Orphan exclusivity	Not applicable to the core product
Current commercial protection	Brand recognition, supply, contracts, and manufacturing economics

Metoprolol succinate is therefore a mature generic market. A new entrant should not base its business case on residual compound exclusivity. The relevant opportunity is operational: securing reliable supply, obtaining an AB-rated product, reducing cost per tablet, or introducing a differentiated delivery format.

How strong is the metoprolol succinate patent estate?

The U.S. patent estate is weak for a standard extended-release tablet based on the established Toprol-XL concept. The strongest potential protection lies in narrow improvements, including:

• Novel multiparticulate structures.
• Specific polymer ratios.
• Controlled-release coatings with defined permeability.
• Abuse-deterrent or dose-dumping-resistant systems.
• Sprinkle products with validated pharmacokinetic performance.
• Orally disintegrating systems that preserve extended release.
• Manufacturing processes that improve content uniformity or coating consistency.

Narrow patents may still have limited commercial value if competitors can design around the claimed excipient ratios or process steps. Patent strength depends on claim breadth, written-description support, enablement, prosecution history, and the ability to demonstrate a meaningful clinical or manufacturing advantage.

What commercial opportunities exist for metoprolol succinate?

Conventional generic tablets

The largest opportunity remains a reliable, low-cost generic product in the four approved strengths. Products can compete through:

• Lower cost of goods.
• High manufacturing yield.
• Consistent dissolution.
• Dual-source or multi-source API procurement.
• Contract pharmacy and wholesaler access.
• Stable supply during competitor shortages.

The product is suitable for manufacturers with established oral-solid-dose capacity but offers limited differentiation.

Authorized generic or private-label supply

Private-label distribution can create value without building a consumer brand. Potential customers include:

• Pharmacy benefit managers.
• Retail chains.
• Group purchasing organizations.
• Hospital systems.
• Regional distributors.
• Government procurement programs.

The commercial model depends on transfer pricing, supply guarantees, quality agreements, and the ability to maintain multiple strengths.

Sprinkle and swallowing-impaired formulations

A capsule containing controlled-release pellets could address patients who cannot swallow conventional tablets. The key development requirement is that the pellets retain their release characteristics after administration with soft food or liquid.

This opportunity requires more than changing the dosage form. The developer must establish:

• Uniform pellet dispersion.
• Stability after opening.
• Acceptable taste and mouthfeel.
• No pellet crushing during administration.
• Preserved pharmacokinetics.
• Clear instructions for food administration.

Orally disintegrating extended-release tablets

An orally disintegrating tablet could target elderly patients, patients with dysphagia, and home-care settings. The technical challenge is maintaining a controlled-release system while achieving rapid oral disintegration.

A coated-multiparticulate design is more suitable than a simple hydrophilic matrix because the tablet must disintegrate quickly without destroying the release-controlling units.

Combination products

Metoprolol succinate could be paired with products used in cardiovascular disease, including antihypertensive agents or diuretics. Combination products may improve adherence but face additional regulatory, dosing, and reimbursement barriers.

The combination must demonstrate compatibility, dosage justification, and bioequivalence or clinical benefit under the applicable FDA pathway. Patent value may be greater than for the standalone generic, but so is development risk.

Which companies are challenging or competing with Toprol-XL?

The U.S. market includes multiple generic manufacturers and distributors. Competition has historically included large generic companies and vertically integrated suppliers such as Sandoz, Dr. Reddy’s Laboratories, Wockhardt, Mylan, Par Pharmaceutical, and other ANDA holders, depending on the specific strength and market period.

Competitive analysis should distinguish among:

• ANDA sponsor.
• Finished-dose manufacturer.
• API supplier.
• Labeler.
• Authorized generic distributor.
• Therapeutically equivalent product.
• Product with temporary supply interruption.

FDA’s Orange Book and Drugs@FDA databases are the controlling sources for current approval and therapeutic-equivalence information. IQVIA, Symphony Health, CMS data, and wholesaler data are required for current volume and price estimates.

What generic entry risks exist?

The principal risks are commercial rather than patent-based.

Price erosion

Multiple AB-rated suppliers can reduce net prices rapidly. A new entrant should model several suppliers rather than assume first-entry economics.

Manufacturing failure

Modified-release products are vulnerable to dissolution failures, coating variability, and out-of-specification results. A single site failure can interrupt supply across all strengths.

API concentration

Metoprolol succinate API may be available from multiple sources, but qualification and change control can delay substitution. API particle size, polymorphism, residual solvents, and impurity profiles must be assessed.

Strength-specific problems

A product can perform acceptably at 25 mg but fail at 200 mg because of altered tablet geometry, drug loading, or polymer-to-drug ratio. Each strength requires an integrated formulation and dissolution strategy.

Label and administration errors

The product must clearly communicate once-daily use and the prohibition on crushing or chewing. Instructions for tablet splitting, if permitted by the approved label, must be supported by score-line performance and dose uniformity.

How does metoprolol succinate compare with metoprolol tartrate?

Factor	Metoprolol succinate ER	Metoprolol tartrate
Release	Extended	Immediate or conventional
Typical dosing	Once daily	Often twice daily
Reference brand	Toprol-XL	Lopressor
Main formulation challenge	24-hour controlled release	Rapid and consistent release
Patient value	Convenience and smoother exposure	Flexible short-duration dosing
Generic complexity	Higher	Lower
Excipient strategy	Polymer matrix or coated particles	Conventional immediate-release tablet
Substitution	Not automatically interchangeable	Separate product and indication analysis

Metoprolol succinate has a stronger adherence proposition because of once-daily dosing, but its formulation and regulatory pathway are more demanding than those for metoprolol tartrate.

What manufacturing and IP barriers affect market entry?

A conventional product requires a robust oral-solid-dose platform, qualified excipient suppliers, and dissolution capability that can discriminate between formulations. The most important manufacturing controls include:

• API particle-size distribution.
• Blend uniformity.
• Granule endpoint.
• Polymer distribution.
• Coating weight gain.
• Tablet hardness.
• Friability.
• Dissolution across pH conditions.
• Stability under accelerated and long-term storage.

The most defensible IP strategy is a narrow improvement patent tied to a commercially meaningful advantage. Examples include reduced food effect, improved storage stability, lower variability across strengths, or a sprinkle system that preserves release after administration. Broad claims covering standard hypromellose or ethylcellulose matrices are likely to face validity and design-around challenges.

What licensing deals affect metoprolol succinate?

Historical commercial rights to Toprol-XL and generic distribution have changed among brand owners, generic companies, and distributors. Licensing is most relevant today for:

• Authorized-generic supply.
• Regional commercialization.
• Contract manufacturing.
• API sourcing.
• Technology transfer for coated multiparticulates.
• Private-label distribution.

A transaction should separate the ANDA, manufacturing site, trademarks, formulation know-how, regulatory files, stability data, and supply contracts. A license to the brand name does not necessarily transfer the generic application or the underlying manufacturing technology.

Key Takeaways

• Metoprolol succinate extended-release tablets are a mature, off-patent generic opportunity.
• The main formulation challenge is reproducing a stable 24-hour release profile for all four strengths.
• Hypromellose matrices offer the lowest-cost entry route.
• Ethylcellulose coatings and multiparticulate systems provide stronger differentiation but increase manufacturing complexity.
• Sprinkle capsules and orally disintegrating extended-release products offer the clearest formulation-led opportunities.
• The historical Toprol-XL formulation patent estate no longer creates a broad U.S. barrier to conventional generic entry.
• Current Orange Book status, approved ANDAs, therapeutic-equivalence ratings, and applicant-specific patent certifications must be checked before launch or acquisition.
• Commercial success depends on cost of goods, supply continuity, dissolution performance, channel access, and manufacturing reliability.
• Biosimilar risk is not relevant because metoprolol succinate is a small-molecule drug, not a biologic.
• Generic price erosion and multi-source competition are the dominant commercial risks.

FAQs

Is metoprolol succinate a biologic subject to biosimilar competition?

No. Metoprolol succinate is a chemically synthesized small molecule. Competition occurs through generic drug applications, not biosimilar applications.

Can metoprolol succinate extended-release tablets be crushed?

No. Crushing or chewing can disrupt controlled release and increase the rate of drug release. Product-specific labeling must control administration instructions.

Which excipient is most important for metoprolol succinate extended release?

The release-controlling polymer is generally the most important excipient category. Hypromellose and ethylcellulose can materially affect hydration, permeability, dissolution, and pharmacokinetics.

Is metoprolol succinate interchangeable with metoprolol tartrate?

No. The products differ in salt form, release profile, dosing frequency, labeling, and regulatory approval. Interchangeability requires the applicable regulatory determination.

What is the best differentiated product strategy?

A controlled-release multiparticulate product designed for sprinkle administration is the strongest differentiation path. It has greater technical and regulatory risk than a standard tablet but can address swallowing difficulty and create narrower competition than a conventional generic.

References

1. U.S. Food and Drug Administration. (2023a). Toprol-XL (metoprolol succinate) extended-release tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023b). Drugs@FDA: Toprol-XL, NDA 019962. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2012). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. FDA.

5. U.S. Food and Drug Administration. (2017). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. FDA.

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.